Hi Skypilot.
On Friday Alan said the top 5 patents coming off in 2013 that could use UNIFILL was $26 Billion the top one being $8 + Billion. so 26B - 70% = 7.8B (This is the amount the pharma keeps). if unifill can stop the slide of revenue loss @ 50% then unis is negotiating for a % of this 20%. DYO Sums. (Alans words were QUOTE " THE % THE PHARMAS ARE THINKINS IS A LOT DIFFERENT TO WHAT HE IS THINKING") The room giggled.
I missed the date but Alan said they are waiting on a rulling to Determine if a drug can be revalidated with new patent protection by saying the drug without the unifill syringe was no longer safe ("or the safest").
Cheers.
- Forums
- ASX - By Stock
- UNS
- ramblings of a mad ramper
ramblings of a mad ramper, page-22
-
-
- There are more pages in this discussion • 8 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add UNS (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
SBW
SHEKEL BRAINWEIGH LTD
Dani Nadri, Country Manager Australia
Dani Nadri
Country Manager Australia
SPONSORED BY The Market Online